Douleur Therapeutics Inc

San Diego, CA · Biotech · Private

Therapeutic molecules for chronic pain treatment

Grants
$1.3M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Pre-clinical evaluation of DT-001, a small molecule antagonist of MD2-TLR4 for utility in the treatment of pain.$646,527
Federal grantDepartment of Health and Human Services · Phase I · Pre-clinical evaluation of DT-001, a small molecule antagonist of MD2-TLR4 for utility in the treatment of pain.$646,527
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2102Autolus Therapeutics——
2103INVENUX, LLC——
2104Legacy Lyfe Holdings, LLC—$5.3M
2105Douleur Therapeutics Inc——
2106YEWSAVIN, INC.——
2107NEUROTHERANOSTICS, INC.——
2108Twenty-Two Desserts, Inc.—$1.4M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.